Top 4 facts life science companies need to know about the UPC

Top 4 facts life science companies need to know about the UPC
The UPC has been a long-awaited project and it will represent the biggest change in recent patent history. What will be the real commercial impact of the UPC? What can pharmaceutical and biotechnological companies do to prepare now? Ahead of the inaugural Life Sciences IP Summit (28th - 29th November 2017), we asked Dr Matthias Zigann, Presiding Judge at the Munich Regional Court to explain the top four facts life science companies need to know regarding the implementation of the UPC treaty and the future of the European patent landscape.

Please note: That all fields marked with an asterisk (*) are required.